daiichisankyo.us Open in urlscan Pro
52.168.54.37  Public Scan

Form analysis
1 forms found in the DOM

Name: hrefFm — POST #

<form action="#" id="hrefFm" method="post" name="hrefFm"><span></span></form>

Text Content

Skip to content
Passion for innovation. Compassion for Patients.
Healthcare Professionals | Careers | Contact Us | Worldwide |
Search Search Search

 * About Us
   * About Us
   
   
   * WHO WE ARE
     
     * Values and Mission
     * Company Culture
     * Global Business Strategy and Midterm Plan
     * History
     * Corporate Philanthropy
   
   
   * PARTNERSHIPS
     
     * Business Development
     * Alliances At-A-Glance
   
   
   * CORPORATE INFORMATION
     
     * Corporate Management
     * Company Governance and Global Structure
     * Corporate Brochure
   
   
   * PATIENT ADVOCACY
 * Responsibility
   * Responsibility
   
   
   * COMPLIANCE
     
     * Standards Of Business Conduct
     * Standards of Business Conduct & Ethics for Third Parties
     * Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy
     * California Compliance Declaration
     * California Supply Chains Act
     * Daiichi Sankyo Group Employee Code of Conduct
   
   
   * TRANSPARENCY AND DISCLOSURE
     
     * Post-marketing Commitments
     * CME and Charitable Contributions Disclosure
     * Working with Healthcare Professionals
     * Vermont Pharmaceutical Marketer Price Disclosure
     * Clinical Trial Information Disclosure
   
   
   * CORPORATE GIVING AND SUPPORT
     
     * Daiichi Sankyo Requirements
     * Charitable Contributions
     * Sponsorships
     * Corporate Support FAQs
     * Patient Advocacy Support
     * Independent Medical Education (IME)
   
   
   * DAIICHI SANKYO PATIENT SUPPORT PROGRAMS
   
   
   * SUPPLIER DIVERSITY
     
     * Supplier Registration
     * Supplier Diversity FAQs
   
   
   * TRANSPARENCY IN COVERAGE
   
   
   * RIGHTS & PROTECTIONS AGAINST SURPRISE MEDICAL BILLS
 * Research & Development
   * Research & Development
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   
   
   * EXPANDED ACCESS TO INVESTIGATIONAL PRODUCTS
   
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories
   * Our Stories
   
   
   * FORMER HEART SURGEON FINDS REWARDING CAREER OUTSIDE THE OR


Search Search Button
 * 
   About Us
   * 
     Who We Are
     * Who We Are
     * Values and Mission
     * Company Culture
     * Global Business Strategy and Midterm Plan
     * History
     * Corporate Philanthropy
   * 
     Partnerships
     * Partnerships
     * Business Development
     * Alliances At-A-Glance
   * 
     Corporate Information
     * Corporate Information
     * Corporate Management
     * Company Governance and Global Structure
     * Corporate Brochure
   * Patient Advocacy
 * 
   Responsibility
   * 
     Compliance
     * Compliance
     * Standards Of Business Conduct
     * Standards of Business Conduct & Ethics for Third Parties
     * Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy
     * California Compliance Declaration
     * California Supply Chains Act
     * Daiichi Sankyo Group Employee Code of Conduct
   * 
     Transparency and Disclosure
     * Transparency and Disclosure
     * Post-marketing Commitments
     * CME and Charitable Contributions Disclosure
     * Working with Healthcare Professionals
     * Vermont Pharmaceutical Marketer Price Disclosure
     * Clinical Trial Information Disclosure
   * 
     Corporate Giving and Support
     * Corporate Giving and Support
     * Daiichi Sankyo Requirements
     * Charitable Contributions
     * Sponsorships
     * Corporate Support FAQs
     * Patient Advocacy Support
     * Independent Medical Education (IME)
   * Daiichi Sankyo Patient Support Programs
   * 
     Supplier Diversity
     * Supplier Diversity
     * Supplier Registration
     * Supplier Diversity FAQs
   * Transparency in Coverage
   * Rights & Protections Against Surprise Medical Bills
 * 
   Research & Development
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   * Expanded Access to Investigational Products
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories
   * Former Heart Surgeon Finds Rewarding Career Outside the OR
 * Healthcare Professionals
 * Careers
 * Contact Us


HOME_PAGE_HEADER_CONTENT

Passion for Innovation.

Compassion for Patients.




LEARN MORE-HP UPDATED


LEARN MORE

Your browser does not support the video tag.

Corporate Video

For people affected by cancer, Daiichi Sankyo turns hope into possibility.
Possibility into reality. Our collective craft is medicine. We’re transforming
how cancer and other disease are treated. More than 120 year of heritage
inspires us to meet new challenges.

 
My Greatest Professional Adventure—10 Years in the Making

Ken Keller, President & CEO, Daiichi Sankyo, Inc., and Global Head of Oncology
Business on the adventure of a lifetime and how each new one shapes who he is.
read more

 
Those Who Raise You Up: Head of Clinical Science Reflects on Her Role Models

Dalal Nesheiwat discusses her PharmD experience and the role of family and
mentorship in her pursuit of a fulfilling career. read more

 
Former Heart Surgeon Finds Rewarding Career Outside the OR

Michael Grosso talks open heart surgery, Specialty Medicine, and Astronomy. read
more




FEATURED NEWS


PRESS RELEASES

Email Alert
Fri Apr 05 00:00:00 GMT-05:00 2024 NEW
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for
Previously Treated Patients with Metastatic HER2 Positive Solid Tumors Download
Wed Apr 03 00:00:00 GMT-05:00 2024 NEW
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in
Patients with Platinum-Resistant Ovarian Cancer Download
Tue Apr 02 00:00:00 GMT-05:00 2024 NEW
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for
Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast
Cancer Download
Mon Feb 19 00:00:00 GMT-05:00 2024
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for
Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Download
View All



 * ABOUT US
   
   * Who We Are
   * Partnerships
   * Corporate Information
   * Patient Advocacy


 * RESPONSIBILITY
   
   * Compliance
   * Transparency and Disclosure
   * Corporate Giving and Support
   * Daiichi Sankyo Patient Support Programs
   * Supplier Diversity
   * Transparency in Coverage
   * Rights & Protections Against Surprise Medical Bills


 * RESEARCH & DEVELOPMENT
   
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   * Expanded Access to Investigational Products
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories
   * Former Heart Surgeon Finds Rewarding Career Outside the OR

 * LinkedIn
 * Twitter
 * Facebook
 * Youtube

   
 * Terms & Conditions
 * Privacy Notice
 * Contact Us
 * Site Map

© 2024 Daiichi Sankyo, Inc. All Rights Reserved.
go to top


WORLDWIDE

Daiichi Sankyo Co., Ltd - Global


ASIA

 * Japan
 * China
 * Hong Kong
 * Korea
 * Taiwan
 * Thailand
 * Vietnam


AMERICAS

 * Brazil

USA

 * Daiichi Sankyo, Inc.
 * American Regent, Inc.
 * Plexxikon


EUROPE

 * Daiichi Sankyo
   Europe
 * Austria
 * Belgium
 * France
 * Germany
 * Ireland

 * Italy
 * Portugal
 * Spain
 * Switzerland
 * The Netherlands
 * Turkey
 * United Kingdom



Continue Return